Millendo Therapeutics Announces Data Presentation for Nevanimibe at ENDO 2018

ANN ARBOR, Mich.--()--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that data from its nevanimibe (ATR-101) program will be presented in an oral presentation at The Endocrine Society’s (ENDO) 100th Annual Meeting and Expo, being held March 17-20, 2018 in Chicago, Illinois. The presentation will contain a discussion of clinical results from a Phase 2 proof-of-concept study of nevanimibe in classic congenital adrenal hyperplasia (CAH), a rare inherited endocrine disease characterized by abnormal hormone levels and overgrowth of the adrenal glands.

Details of the oral presentation are as follows:

Title: A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Oral Session Number: OR19
Session Name: Adrenal Insufficiency and Adrenal Tumor
Date/ Time: Monday, March 19, 2018, 12:15 – 12:30 PM CDT
Location: McCormick Place West, Room W187

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing livoletide for the treatment of Prader-Willi Syndrome (PWS) and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. www.millendo.com

Contacts

MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com

Recent Stories

RSS feed for Millendo Therapeutics, Inc.

Release Summary

Millendo Therapeutics announced that data from its nevanimibe (ATR-101) program will be presented in an oral presentation at ENDO 2018.

Millendo Therapeutics, Inc.